Black FridayUp to 80% OFF
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals IncorporatedVertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsETFs

Trade ideas

VRTX QuantSignals V3 Earnings 2025-11-03VRTX QuantSignals V3 Earnings 2025-11-03 VRTX Earnings Signal | 2025-11-03 • Direction: NEUTRAL | Confidence: 65% • Entry Plan: Pre Earnings Close | Expiry 2025-11-07 • Strike Focus: $360.00 • Entry Range: $66.20 • Target 1: $99.30 • Stop Loss: $46.34 • Implied Move: $32.10 (7.8%) • 24h Move: -1.90% • Flow Intel: Neutral | PCR 1.22 • ⚠️ MODERATE RISK WARNING: Consider reducing position size due to moderate confidence level. • Earnings Date: 2025-11-03 | Estimate: $4.65 ⚖️ Compliance: Educational earnings analysis for QS Premium members only. Not financial advice. 🎯 TRADE RECOMMENDATION Direction: BUY CALLS Confidence: 65% Conviction Level: MEDIUM 🧠 ANALYSIS SUMMARY Katy AI Signal: NEUTRAL (50% confidence) but with $416.72 target (+1.6% from current price) - suggests slight bullish bias despite neutral classification Technical Analysis: EMA alignment bullish, RSI 65.2 (neutral but leaning bullish), MACD positive at 5.8337, recent 24h pullback of -1.90% may provide entry opportunity News Sentiment: Strongly bullish - Q3 EPS beat ($4.80 vs $4.56 estimate), sales beat ($3.076B vs $3.053B), raised FY2025 sales guidance Options Flow: Neutral PCR 1.22, but max pain at $412.50 (+0.6%) suggests upside pressure, implied move of 7.8% provides room for volatility Risk Level: MODERATE - Low volume concern, but strong fundamental beat supports directional bias 💰 TRADE SETUP Expiry Date: 2025-11-07 (4 days) Recommended Strike: $360.00 Entry Price: $66.20 - $66.20 (mid price from table) Target 1: $99.30 (50% gain from entry) Target 2: $132.40 (100% gain from entry) Stop Loss: $46.34 (30% loss from entry) Position Size: 3% of portfolio (moderate conviction with strong news catalyst) ⚡ COMPETITIVE EDGE Why This Trade: Strong earnings beat combined with raised guidance creates fundamental momentum that technicals and options flow support Timing Advantage: Pos Image QS Analyst APP — 6:23 PM t-earnings dip of -1.90% provides better entry, 4-day expiry captures short-term momentum without excessive time decay Risk Mitigation: Conservative delta (0.751) provides high probability of profitability, stop loss protects against earnings volatility surprises 🚨 IMPORTANT NOTES Katy AI shows neutral confidence (50%) but targets upside to $416.72 Volume running 0.0x average indicates low market participation - monitor for volume confirmation Despite beat rate history of 50%, current quarter showed strong outperformance Consider scaling into position given mixed signals but strong fundamental catalyst 📊 TRADE DETAILS 📊 🎯 Instrument: VRTX 🔀 Direction: CALL (LONG) 🎯 Strike: 360.00 💵 Entry Price: 66.20 🎯 Profit Target: 99.30 🛑 Stop Loss: 46.34 📅 Expiry: 2025-11-07 📏 Size: 3.0 📈 Confidence: 65% ⏰ Entry Timing: N/A 🕒 Signal Time: 2025-11-03 21:23:49 EST ⚠️ MODERATE RISK WARNING: Consider reducing position size due to moderate confidence level.
NASDAQ:VRTXLong
by quantsignals
2
VRTX Tight Triangle Breakout – Watch Closely 🧠 Chart Analysis Summary: Pattern: A symmetrical triangle is visible, tightening toward the apex with a breakout just forming. Current Price: $472.47 (breakout near) Key Levels: Support Zone: Around $468–470 (white/yellow zone) Resistance Zone: First Target: $477.01 (red line) Major Target: $482.20 (green line) Volume Confirmation: Suggested to confirm breakout with volume increase. 📊 Trade Idea (Long Setup): Entry: $472.50–473.00 Target 1: $477.00 Target 2: $482.00 Stop-Loss: Below $468.00
NASDAQ:VRTXLong
by ProfittoPath
VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH (1/9) Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀 (2/9) – REVENUE RUSH • Q4 Haul: $ 2.91B—16% jump from last year 💥 • Full ‘24: $ 11.02B, up 12%—Trikafta’s king 📊 • ‘25 Outlook: $11.75-$ 12B—6-9% growth NYSE:CF keeps humming—newbies add zest! (3/9) – BIG WINS • Journavx: Non-opioid painkiller greenlit Jan ‘25 🌍 • Alyftrek: CF drug for 6+—ships now 🚗 • Cash: $11.2B—loaded for action 🌟 NASDAQ:VRTX storms pain—CF stays golden! (4/9) – SECTOR CHECK • Valuation: 11x sales—above 9x avg 📈 • Vs. Peers: Gilead’s 4x, Regeneron’s 8x—premium? • Growth: 12% beats biotech’s 5-7% 🌍 NASDAQ:VRTX flexes—value or stretch? (5/9) – RISKS ON TAP • Payers: Journavx needs coverage—hiccups? ⚠️ • Trikafta: 93% of sales—big lean 🏛️ • Comp: Pain rivals, CF safe—for now 📉 Hot streak—can it dodge the bumps? (6/9) – SWOT: STRENGTHS • CF King: Trikafta, Alyftrek lock it in 🌟 • Pain Play: Journavx eyes $ 4B peak 🔍 • Cash: $11.2B—war chest ready 🚦 NASDAQ:VRTX ’s got muscle and moolah! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Trikafta reliance—eggs in one basket 💸 • Opportunities: Casgevy rolls, pain grows 🌍 Can NASDAQ:VRTX zap past the risks? (8/9) – NASDAQ:VRTX ’s Q4 surge—what’s your vibe? 1️⃣ Bullish—Pain pays off big. 2️⃣ Neutral—Solid, but risks linger. 3️⃣ Bearish—Growth hits a wall. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:VRTX ’s $2.91B Q4 and Journavx/Alyftrek wins spark buzz—$11.2B cash backs it 🌍🪙. Trikafta rules, risks hover—champ or chaser?
NASDAQ:VRTXLong
by DCAChampion
Vertex Pharmaceuticals Pulls Back After RallyVertex Pharmaceuticals ended January with a big rally. Now, after a pullback, some traders may see an opportunity. The first pattern on today’s chart is the price gap on January 31 after the FDA approved its Journavx painkiller. (It’s the first of its kind to treat pain in a unique way without addiction risks.) The stock has retraced the surge, which may appeal to dip buyers. Second is the October 7 close of $448.60. VRTX held that level in late November and again on December 18 before gapping down. The stock is now trying to stabilize in the same location, suggesting support may remain in effect. Next, the MACD surge in January could reflect bullish short-term momentum. Prices are also trying to hold the rising 21-day exponential moving average. Finally, VRTX is near its 50-, 100- and 200-day simple moving averages. That may create potential for the longer-term trend to accelerate if the short-term strength continues. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NASDAQ:VRTX
by TradeStation
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associated with traditional analgesics. The significance of this development cannot be overstated, as it promises a new era where acute pain can be treated effectively and safely, potentially altering the landscape of medical treatment for millions. Journavx operates by selectively inhibiting NaV1.8, a sodium channel vital for pain signaling, thus preventing pain signals from reaching the brain. This mechanism not only offers relief but does so without the side effects that have long plagued opioid use. The implications for healthcare are profound, offering doctors and patients alike a tool that can redefine how we approach pain management in clinical settings. Vertex's success with Journavx showcases the company's commitment to pioneering treatments that address some of the most pressing needs in modern medicine. Financially, this approval has bolstered Vertex's market position, evidenced by a significant uptick in stock performance following the announcement. With a revenue projection for 2025 set between $11.75 and $12.0 billion, Vertex is not just riding the wave of this single approval but is also expanding its therapeutic horizons. The strategic leadership transitions announced alongside this approval signal a robust plan for future innovation, challenging investors and healthcare professionals to think about the evolving landscape of drug development and patient care.  This moment invites us to ponder the future of pharmaceuticals - one where efficacy does not compromise safety, where innovation in treatment could lead to broader societal benefits by reducing dependency on addictive substances. Vertex's journey with Journavx might just be the beginning of a new chapter in medical science, urging us to envision a world where pain management is humane and humane-centered.
NASDAQ:VRTXLong
by UDIS_View
Vertex Pharmaceuticals (VRTX) | Chart & Forecast SummaryRight Here You Can See Vertex Pharmaceuticals Incorporated (VRTX) Registered As (VRTX) On The New York Stock Exchange, Vertex Pharmaceuticals Incorporated Is An American Biopharmaceutical Company Based In Boston, Massachusetts. The Following Chart & Forecast Summary On Vertex Pharmaceuticals Incorporated (VRTX) Has been Subject On Key Indicators on A Trade Set Up in General Like A 1. A Push Set Up 2. A Range Set up 3. And A Break & Retest Set Up Overall Conclusion | Like The Trade Plan Execution & Risk Management on Demand It Tells Us "Long Bias For Now"
CAPITALCOM:VRTXLong
by UnknownUnicorn87383881